康希诺生物

Information Disclosure

Home >Investor Relations >Information Disclosure

H Share

Monthly Return of Equity Issuer on Movements in Securities
VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE I/II CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR PCV24
Form of Proxy for use at the 2025 Annual General Meeting to be held on Wednesday, June 10, 2026
NOTICE OF 2025 ANNUAL GENERAL MEETING
2025 AGM CIRCULAR
VOLUNTARY ANNOUNCEMENT - THE CENTER FOR DRUG EVALUATION, NMPA GRANTED PRIORITY REVIEW STATUS TO NDA FOR TD5CP ADOLESCENT AND ADULT
Monthly Return of Equity Issuer on Movements in Securities
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND THE RULES OF PROCEDURES
FIRST QUARTERLY REPORT FOR THE THREE MONTHS ENDED MARCH 31, 2026
Letter to Non-registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications and Reply Form

1 2 3 4 5 6 52